Fermion's TYK2 JH2 Inhibitor FZ007-119 Granted IND Approval by China NMPA

Contributed by: PR Newswire

Tags

Guangzhou-TYK2-JH2

More Like This

Fermion announces IND Approval of Non-Addictive Pain Relief Drug FZ008-145 by China NMPA

JJP Biologics Announces Positive Decision to Execute a First-in-Human Clinical Trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89)

Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)

Clinical Trial Application (IND) for BioRay Pharmaceutical's BR105 Injection Receives U.S. FDA Approval

HanchorBio Announces Taiwan FDA IND Approval for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma

PR Newswire associated0

Dragonfly Therapeutics to Present Preclinical Data on Clinical-Stage DF6215, its Engineered IL-2R alpha-active Agonist, and DF9001, its EGFR-targeting TriNKET®, at the Society for Immunotherapy of Cancer (SITC) Annual Conference

Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting